

**IN THE UNITED STATES DISTRICT COURT  
FOR THE NORTHERN DISTRICT OF ILLINOIS  
EASTERN DIVISION**

|                                    |   |                               |
|------------------------------------|---|-------------------------------|
| In re: TESTOSTERONE                | ) |                               |
| REPLACEMENT THERAPY                | ) |                               |
| PRODUCTS LIABILITY LITIGATION      | ) | MDL No. 2545                  |
|                                    | ) |                               |
| This document relates to all cases | ) | Honorable Matthew F. Kennelly |


**CASE MANAGEMENT ORDER # 25**  
**(PSC's Motion to Compel Safety Information about**  
**other Testosterone-Containing Products)**

The parties came before the Court on the Plaintiffs' Steering Committee's Motion to Compel the Production of Documents Pertaining to the Safety of Exogenous Testosterone from the AbbVie Defendants. This matter has been fully briefed, and the Court heard argument from both the PSC and AbbVie on August 14, 2015. Based on the papers and the argument, the motion is granted to the extent stated in open court on August 14, 2015, which is as follows:

1. AbbVie shall produce any document collected using the agreed upon set of search terms, that includes information regarding the safety of other testosterone-containing products (as separately identified to plaintiffs), whether or not that product was ever commercialized. Further, to the extent not already collected and produced, AbbVie shall produce the Clinical Study Reports for any clinical trial it conducted regarding other testosterone-containing products. Additionally, to the extent that AbbVie is or becomes aware that additional responsive information has been separately maintained in a dedicated storage area that has not yet been searched, collected or reviewed, AbbVie shall notify the PSC of the same and the parties shall confer regarding such materials.

2. Based on AbbVie's representation that serious adverse events for the other testosterone-containing products for which AbbVie has conducted clinical trials are contained in AEGIS, subject to the agreed upon parameters for production of AbbVie's AEGIS database, AbbVie shall produce those entries in AEGIS that report adverse event information arising out of AbbVie's clinical trials/investigations related to other non-commercialized testosterone-containing products.

SO ORDERED the 21st day of October, 2015.

  
\_\_\_\_\_  
Hon. Matthew F. Kennelly  
Judge of the United States District Court